Drug Search Results
More Filters [+]

INI-2004

Alternative Names: INI-2004, INI2004, INI 2004
Latest Update: 2024-07-30
Latest Update Note: News Article

Product Description

INI-2004 is an allergen agnostic immunotherapy that binds and activates Toll-like receptor 4. When delivered intranasally, INI-2004 dramatically reduced measures of AR in pre-clinical animal models.

Mechanisms of Action: TLR4 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Inimmune
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INI-2004

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

INI-2004-101

P1

Recruiting

Rhinitis, Allergic

2024-11-01

Recent News Events